Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3459-3465

  May, Kenneth F ^a   Chen, Lieping ^b   Zheng, Pan ^a   Liu, Yang ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; TUMOR REJECTION ANTIGEN; TUMOR REJECTION ANTIGEN P1A; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR REJECTION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; DNA-BINDING PROTEINS; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMACYTOMA; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037096878     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Inducible T cell antigen 4-1BB: Analysis of expression and function
2. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
3. Costimulation of CD28- T lymphocytes by 4-1BB ligand
4. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-primed splenic B cells
5. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses
6. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
7. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
8. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
9. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses
10. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
11. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation
12. Immunomodulatory gene therapy with interleukin-12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model
13. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumor and host cells
14. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors
15. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors
16. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death
17. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
18. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
19. Cytotoxic T lymphocytes to an unmutated tumor antigen P1A: Normal development but restrained effector function
20. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells
21. Determination of lymphocyte division by flow cytometry
22. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
23. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
24. + T cell adoptive immunotherapy
25. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
26. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens
27. Viral immune evasion due to persistence of activated T cells without effector function
28. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis
29. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia